Krystal announces positive results from GEM-2 study of KB103
Category: #healthcare  By Mateen Dalal  Date: 2019-06-26
  • share
  • Twitter
  • Facebook
  • LinkedIn

Krystal announces positive results from GEM-2 study of KB103

The pharmaceutical company received Regenerative Medicine Advanced Therapy designation from FDA for KB103

Krystal Biotech, Inc., a gene therapy company recently announced positive results from a Phase 2 clinical trial of KB103 (the GEM 2 study) and an update on results from Phase 1 trial – the GEM 1 study.

Reportedly, in the Phase 2 clinical trial, two patients of ages 22 & 19 and two pediatric patients of ages 14 & 15 with severe generalized RDEB (recessive dystrophic epidermolysis bullosa) were enrolled in December, last year. Prior to dosing, 3 wounds of size up to 20 cm2 were selected on each patient for the trial & then randomized to receive placebo or KB103 in a ratio of 2:1. In the trial results, a total of two KB103 treated chronic wounds and four KB103 treated recurring wounds were included.

Having confirmed the presence of COL7 (type VII collagen) & anchoring fibrils in the Phase 1 part of the trial and acknowledged by Food & Drug Administration, the endpoints of the Phase 2 part were revised towards a focus on clinical improvement.

As per sources close to the matter, 1 of the 4 patients dropped out of the trial voluntarily. The dropout was unrelated to any safety issues with KB103. The Phase 2 analysis was conducted on remaining 3 patients (three placebo treated wounds and six KB103 treated wounds). Out of the 6 wounds that were KB103-treated in patients enrolled for the duration of the Phase 2 trial, 4 were categorized as recurring and 2 were categorized as chronic, based on patient reporting. Recurring wounds open and close spontaneously while chronic wounds remain open for greater than 12 weeks.

Earlier, in the Phase 1 trial, 2 adult patients with severe generalized recessive dystrophic epidermolysis bullosa were evaluated. In each patient, 2 wounds with a surface area of 10 cm2 were randomized to receive placebo or topical KB103.

Source credits: http://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-positive-results-phase-2-clinical

About Author

Mateen Dalal    

Mateen Dalal

Despite working as a professional testing engineer, Mateen Dalal always held a liking for content creation. Following his passion, he now pens down articles for itresearchbrief.com and a couple of similar portals. Mateen is a qualified electronics and telecommunicat...

Read More>>

More News By Mateen Dalal

nference software to synthesize scRNA-seq datasets to fight COVID-19
nference software to synthesize scRNA-seq datasets to fight COVID-19
By Mateen Dalal

nference, an augmented intelligence-based biomedical company, reportedly unveiled a software resourc...

Battelle deploys respiratory masks and PEE decontamination system
Battelle deploys respiratory masks and PEE decontamination system
By Mateen Dalal

From developed countries to emerging economies, people across the globe are demanding for protective...

Nexstim bags 2 orders for Navigated Brain Stimulation system in U.S.
Nexstim bags 2 orders for Navigated Brain Stimulation system in U.S.
By Mateen Dalal

Nexstim Plc, a Finland-based medical technology company recently announced to have bagged two n...